JP2010501596A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501596A5
JP2010501596A5 JP2009525863A JP2009525863A JP2010501596A5 JP 2010501596 A5 JP2010501596 A5 JP 2010501596A5 JP 2009525863 A JP2009525863 A JP 2009525863A JP 2009525863 A JP2009525863 A JP 2009525863A JP 2010501596 A5 JP2010501596 A5 JP 2010501596A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
group
condition
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009525863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501596A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2007/001282 external-priority patent/WO2008025099A1/en
Publication of JP2010501596A publication Critical patent/JP2010501596A/ja
Publication of JP2010501596A5 publication Critical patent/JP2010501596A5/ja
Pending legal-status Critical Current

Links

JP2009525863A 2006-08-31 2007-08-31 抗体含有組成物を用いた非感染性の病状の処置および/または予防 Pending JP2010501596A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2006904752A AU2006904752A0 (en) 2006-08-31 Uses for Antibodies
PCT/AU2007/001282 WO2008025099A1 (en) 2006-08-31 2007-08-31 Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions

Publications (2)

Publication Number Publication Date
JP2010501596A JP2010501596A (ja) 2010-01-21
JP2010501596A5 true JP2010501596A5 (cg-RX-API-DMAC7.html) 2010-09-16

Family

ID=39135433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525863A Pending JP2010501596A (ja) 2006-08-31 2007-08-31 抗体含有組成物を用いた非感染性の病状の処置および/または予防

Country Status (8)

Country Link
US (2) US20100297140A1 (cg-RX-API-DMAC7.html)
EP (1) EP2061510B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010501596A (cg-RX-API-DMAC7.html)
CN (1) CN101626784B (cg-RX-API-DMAC7.html)
AU (1) AU2007291891B2 (cg-RX-API-DMAC7.html)
DK (1) DK2061510T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ575918A (cg-RX-API-DMAC7.html)
WO (1) WO2008025099A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046168A1 (en) 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
MX2011011376A (es) 2009-04-27 2012-04-20 Immuron Ltd Preparacion de inmunoglobulina enriquecida con anti-lps, para utilizarse en tratamiento y/o profilaxis de un trastorno patologico.
JP2011026252A (ja) * 2009-07-27 2011-02-10 Kitasato Institute 上皮成長因子受容体に対する卵黄抗体およびその用途
CA2808361A1 (en) 2010-08-17 2012-02-23 Immuron Ltd. Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of inflammatory bowel disease
CA2818827C (en) 2010-11-23 2024-02-13 Pantheryx, Inc. Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
PH12013501137A1 (en) 2010-12-08 2021-06-02 Abbvie Stemcentrx Llc Novel modulators and methods of use
WO2012098256A1 (en) * 2011-01-21 2012-07-26 Université De La Méditerranée Aix - Marseille Ii Anti-cd146 auto-antibodies and uses thereof
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
US20140017174A1 (en) * 2011-11-30 2014-01-16 Raja Atreya Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
RU2016119491A (ru) 2013-11-04 2017-12-11 Пфайзер Инк. Конъюгаты антитела к efna4 с лекарственным средством
RO130965A8 (ro) * 2015-10-16 2017-06-30 Romvac Company S.A. Producerea şi utilizarea oului hiperimun personalizat () în tratamentul psoriazisului
US10792320B2 (en) * 2018-03-28 2020-10-06 Michael Alan Beller Methods for treatment of bladder dysfunction
WO2020176637A1 (en) 2019-02-26 2020-09-03 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract
US11319382B1 (en) 2021-06-28 2022-05-03 King Abdulaziz University Methods for producing and using IgY antibodies targeting the middle east respiratory syndrome coronavirus spike protein to treat or prevent MERS-CoV infection

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3911108A (en) * 1973-02-14 1975-10-07 Diamond Shamrock Corp Process of producing bovine milk products containing specific antibodies
AUPN642795A0 (en) * 1995-11-08 1995-11-30 Northfield Laboratories Pty Ltd Dairy compositions and methods of preparing same
WO1998014209A1 (en) * 1996-10-02 1998-04-09 Ovimmune, Inc. Oral administration of chicken yolk antibodies to treat disease
AU2115799A (en) * 1998-01-19 1999-08-02 Dcv, Inc. Composition and method for treatment and prevention of arthritis and/or autoimmune diseases
WO1999064069A1 (en) * 1998-06-10 1999-12-16 Ophidian Pharmaceuticals, Inc. Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
CN1163511C (zh) * 1999-10-22 2004-08-25 徐永华 鸡卵黄抗白细胞介素-8抗体、制备方法及其应用
CN1303889A (zh) 1999-12-20 2001-07-18 陶氏康宁东丽硅氧烷株式会社 用于嵌件模塑或双模腔模塑的硅橡胶组合物
JP2005298332A (ja) * 2000-09-28 2005-10-27 Shibayagi:Kk 過剰自己抗体産生抑制物質、その製造法およびその使用方法
US20050175597A1 (en) * 2002-03-21 2005-08-11 Rawlin Grant T. Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment
CN1199672C (zh) 2002-04-17 2005-05-04 李永忠 一套预防与治疗癌症中成药
CN1377894A (zh) * 2002-04-23 2002-11-06 郭占军 蛋黄抗癌抗体制备方法及其应用
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
JP4264894B2 (ja) * 2004-03-01 2009-05-20 三菱自動車工業株式会社 エアボックス付きグローブボックス
WO2005090406A2 (en) * 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
CA2584804A1 (en) * 2004-10-21 2006-05-04 The Penn State Research Foundation Eph receptor tumor biomarkers
CA2594636A1 (en) * 2005-01-31 2006-08-10 Genentech, Inc. Anti-ephb2 antibodies and methods using same
CN101253198A (zh) 2005-08-29 2008-08-27 独立行政法人科学技术振兴机构 使用鸵鸟产生的抗体及其制备方法

Similar Documents

Publication Publication Date Title
JP6816098B2 (ja) 粘膜炎症を抑制するためのイガイ接着タンパク質生成物及びその使用
Thapa et al. Application of sol–gels for treatment of gynaecological conditions—physiological perspectives and emerging concepts in intravaginal drug delivery
US10441760B2 (en) Self-actuating chemomechanical devices for delivery and extended release of therapeutic agents in the gastrointestinal tract
JP6076962B2 (ja) 治療薬を局所送達するための感熱性を有する粘膜付着性または皮膚粘着性の浸透促進剤
EA032034B1 (ru) Наночастицы двукратно дериватизованного хитозана и способы их получения и применения для переноса генов in vivo
JP2007526248A5 (cg-RX-API-DMAC7.html)
JP2016515113A5 (cg-RX-API-DMAC7.html)
JP2010501596A (ja) 抗体含有組成物を用いた非感染性の病状の処置および/または予防
JP2019031521A5 (cg-RX-API-DMAC7.html)
JP2010500284A5 (cg-RX-API-DMAC7.html)
WO2013177927A1 (zh) 注射用埃索美拉唑钠冻干粉组合物及其制备方法
US11149275B2 (en) Device and method to treat esophageal disorders
CN107722115A (zh) 一种新型重组蜂毒多肽及其制备方法和应用
TWI482632B (zh) 醫藥用載體及使用該載體的藥物結構
CN102964335B (zh) 一种埃索美拉唑钠化合物及其制备方法和用途
CN106474472A (zh) 肿瘤曲妥珠单抗靶向anti‑miR‑21纳米粒子及其制备方法
WO2013177963A1 (zh) 注射用泮托拉唑钠冻干粉组合物及其制备方法
GR20180100090A (el) Φαρμακευτικο σκευασμα σε μορφη γελης για ασθενεις με ηωσινοφιλικη οισοφαγιτιδα
Xu BIDIRECTIONAL THERMORESPONSIVE GRIPPERS FOR MACROMOLECULAR DRUG DELIVERY
AU2021349286B2 (en) Vaccine compositions for mucosal immune response
CN120643498B (zh) 基于中药成分自载体的可溶性微针穴位敷贴及其制备方法和应用
JP2015534956A5 (cg-RX-API-DMAC7.html)
CN110917478B (zh) 一种宫颈hpv感染用药物缓释器
JP2014118361A5 (cg-RX-API-DMAC7.html)
ES2613585B2 (es) Partículas purificadas de polen y su uso para administrar nanosistemas